ストックスクリーナーアプリを入手
38.21
1.95%
-0.76
アフターアワーズ：
38.40
0.19
+0.50%
前日終値:
$38.97
開ける：
$38.5
24時間の取引高:
1.47M
Relative Volume:
0.72
時価総額：
$2.63B
収益：
$18.09M
当期純損益:
$-208.87M
株価収益率:
-10.88
EPS:
-3.5125
ネットキャッシュフロー:
$-178.15M
1週間 パフォーマンス:
-3.75%
1か月 パフォーマンス:
-19.57%
6か月 パフォーマンス:
+56.79%
1年 パフォーマンス:
+152.88%
1日の値動き範囲:
$38.16
$40.00
1週間の範囲:
$37.33
$40.86
52週間の値動き範囲:
$8.73
$71.50
Uniqure Nv Stock (QURE) Company Profile
Compare QURE vs VRTX, REGN, ARGX, RVMD, ALNY
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
QURE
Uniqure Nv
|
38.21 | 2.68B | 18.09M | -208.87M | -178.15M | -3.5125 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Uniqure Nv Stock (QURE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-11 | アップグレード | Mizuho | Neutral → Outperform |
| 2026-03-09 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2026-03-09 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2026-03-03 | ダウングレード | Mizuho | Outperform → Neutral |
| 2026-03-03 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2026-03-02 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2026-03-02 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2026-02-24 | 開始されました | Wolfe Research | Peer Perform |
| 2026-01-28 | 開始されました | Barclays | Equal Weight |
| 2025-11-04 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2025-08-14 | アップグレード | Mizuho | Neutral → Outperform |
| 2025-04-01 | 再開されました | Chardan Capital Markets | Buy |
| 2024-12-10 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2024-10-10 | 再開されました | Raymond James | Outperform |
| 2024-02-29 | ダウングレード | Goldman | Buy → Neutral |
| 2023-12-19 | ダウングレード | Mizuho | Buy → Neutral |
| 2022-03-17 | アップグレード | UBS | Neutral → Buy |
| 2021-06-15 | 開始されました | BTIG Research | Buy |
| 2021-05-21 | 開始されました | UBS | Neutral |
| 2021-04-26 | 再開されました | Credit Suisse | Outperform |
| 2021-04-01 | アップグレード | Mizuho | Neutral → Buy |
| 2021-01-07 | アップグレード | Guggenheim | Neutral → Buy |
| 2020-11-24 | 開始されました | H.C. Wainwright | Buy |
| 2020-11-11 | 開始されました | Berenberg | Buy |
| 2020-11-09 | 開始されました | Jefferies | Buy |
| 2020-11-04 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-10-23 | 開始されました | RBC Capital Mkts | Outperform |
| 2020-08-25 | 開始されました | Raymond James | Strong Buy |
| 2020-07-31 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2020-06-25 | ダウングレード | Mizuho | Buy → Neutral |
| 2020-06-25 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2020-06-25 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2019-12-03 | 開始されました | Cowen | Outperform |
| 2019-12-03 | 開始されました | Goldman | Buy |
| 2019-11-05 | 開始されました | Credit Suisse | Outperform |
| 2019-10-11 | 開始されました | Stifel | Buy |
| 2019-09-25 | 開始されました | Bernstein | Outperform |
| 2019-09-12 | 開始されました | Mizuho | Buy |
| 2019-07-30 | ダウングレード | Guggenheim | Buy → Neutral |
| 2019-07-08 | 繰り返されました | Cantor Fitzgerald | Overweight |
| 2019-04-12 | 開始されました | Piper Jaffray | Overweight |
| 2019-03-29 | 開始されました | Robert W. Baird | Outperform |
すべてを表示
Uniqure Nv (QURE) 最新ニュース
Uniqure NV (QURE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Kalehua Capital Management LLC Makes New Investment in uniQure N.V. $QURE - MarketBeat
Orbimed Advisors LLC Has $34.93 Million Holdings in uniQure N.V. $QURE - MarketBeat
Uniqure NV (QURE) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Uniqure NV (QURE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
QURE Stock Just Shot Up 8%uniQure’s Much-Talked-About Huntington’s Disease Therapy Gets A UK Boost - Stocktwits
uniQure N.V. Revenue Breakdown – FWB:UQ1 - TradingView
QURE|Uniqure NV|Price:38.970|Chg%:-0.460 - TradingKey
uniQure (QURE) to Release Earnings on Wednesday - MarketBeat
uniQure N.V. Revenue Breakdown – BIVA:QURE/N - TradingView
Siren L.L.C. Makes New $16.35 Million Investment in uniQure N.V. $QURE - MarketBeat
Aberdeen Group plc Reduces Holdings in uniQure NV - GuruFocus
Uniqure NV (QURE) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Earnings Preview: UniQure NV to Report Financial Results Pre-market on July 29 - Moomoo
Which Is a Better Investment, Ionis Pharmaceuticals, Inc. or uniQure N.V. Stock? - AAII
Militia Capital Management LLC Purchases New Shares in uniQure N.V. $QURE - MarketBeat
uniQure N.V. to announce Q2 2026 financial results on July 29 - scanx.trade
uniQure to Announce Second Quarter 2026 Financial Results - The Manila Times
uniQure sets July 29 webcast after Q2 financial results - Stock Titan
uniQure N.V. $QURE Shares Sold by Jennison Associates LLC - MarketBeat
JPMorgan Chase & Co. Increases Stake in uniQure NV - GuruFocus
Goldman Sachs Maintains UniQure NV(QURE.US) With Hold Rating, Maintains Target Price $46 - Moomoo
uniQure (QURE) Proxy filing Summary - Quartr
uniQure (NASDAQ:QURE) Shares Pass Above 50 Day Moving AverageTime to Sell? - MarketBeat
Aberdeen Group plc (QURE) discloses 2.85M-share, 4.52% holding in uniQure - Stock Titan
Is QURE Stock Attractive After Its Rally, Rich Valuation, and Hold? - MSN
What Caused uniQure's Dramatic Stock Plunge - Kavout | AI
uniQure NV | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
uniQure (QURE) Stock Still Looks Expensive Given Its Huntingtons Promise - Yahoo Finance
uniQure Trends to Watch as Gene Therapy Bets Shift Beyond Hemgenix - The Globe and Mail
QURE Stock Outlook Rests on AMT-130, FDA Talks, and Cash Runway - Yahoo Finance
QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit - GuruFocus
UniQure (QURE) now trades above golden cross: Time to buy? - MSN
JPMorgan discloses 7% uniQure (QURE) stake of 4,866,211 shares - Stock Titan
uniQure's Huntington's prospects brighten after FDA shift - S&P Global
If You Invested $1,000 in Uniqure (QURE) - Stock Titan
uniQure N.V. (NASDAQ:QURE) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
The Technical Signals Behind (QURE) That Institutions Follow - Stock Traders Daily
QURE Jumps 20% – Analysts Upgrade Stock On Huntington’s Disease Therapy Update, Retail Eyes $150 - Stocktwits
uniQure N.V. $QURE Shares Purchased by Y Intercept Hong Kong Ltd - MarketBeat
UniQure soars as Cantor upgrades on plans to seek gene therapy nod - MSN
uniQure N.V. (QURE) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
uniQure (QURE) Status Update Summary - Quartr
Uniqure Insider Sold Shares Worth $952,051, According to a Recent SEC Filing - Moomoo
uniQure (QURE) CEO sells 21,082 shares after option exercise under 10b5-1 plan - Stock Titan
QURE INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
Price to sales forward of uniQure N.V. – FWB:UQ1 - TradingView
UniQure surges on plans to seek US nod for gene therapy - MSN
QURE Investors Have Opportunity to Lead uniQure N.V. Class Action - The National Law Review
Uniqure Insider Sold Shares Worth $983,030, According to a Recent SEC Filing - Moomoo
uniQure (QURE) CMO sells 30,000 shares and exercises 10,000 stock options - Stock Titan
Uniqure Nv (QURE) 財務データ
収益
当期純利益
現金流量
EPS
1.97%
0.83%
大文字化:
|
ボリューム (24 時間):